Sep 9, 2021
In this episode, Lance Baldo, MD, discusses the
use of MRD testing, T-cell receptor profiling, and how lessons from
the COVID-19 pandemic will help shape the future of cancer
- Welcome to another exciting episode of Oncology Overdrive
- About Baldo :17
- The interview 1:20
- Tell me about your journey 1:38
- Did you question your decision to leave clinical practice for
an entrepreneurial venture? 2:36
- What does Adaptive Biotechnologies do?
- What is Minimal Residual Disease (MRD) testing and how is it
- Are you looking only at hematologic malignancies?
- How are experts using MRD testing in clinical practice?
- Why do you think MRD testing is important in treating cancers?
- Is Adaptive working on drug discovery and development related
to MRD testing? 9:20
- Personalized care and how real life feels like science fiction
- Doing what’s best for the patient
- Tell me about T-cell receptor profiling
- Tell me about neo-antigen-based therapy
- Are these types of technologies available outside of large,
academic institutions? 22:49
- Has COVID impacted the way you and your team think about
implementing therapies and innovation?
- Do you think what we’ve learned over the last year will help
with the creation of future cancer vaccines?
- If we spoke again in 10 years, what would you hope to have
- Baldo’s take-home message 37:42
- Where to find Baldo 38:57
Lance Baldo, MD, is chief medical officer of
We’d love to hear from you! Send your comments/questions to Dr.
Jain at email@example.com.
Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baldo can be reached on
LinkedIn, via email at firstname.lastname@example.org
and at www.adaptivebiotech.com.
Disclosures: Baldo is chief medical officer of
Adaptive Biotechnologies. Jain reports she is a paid freelance
writer for Lippincott.